Stryker has announced the global commercial launch of its new Trevo XP ProVue retriever, the second generation fully visible stent retriever designed to treat acute ischemic stroke.
The Trevo ProVue retrievers are claimed to be the world's first stent retrievers with full-length visibility.
According to the company, these fully visible stent retrievers are built on Trevo technology, which has delivered strong clinical results and positive patient outcomes for acute ischemic stroke patients.
With this launch, the company expands the ProVue retriever line with additional size and shape options for physicians.
California Pacific Medical Center director of Neurointerventional Services San Francisco, California, Dr Joey D English said: "It has excellent deliverability and the visibility it provides allows me to confidently deploy the device in the best position to capture and remove the clot.
"I can visualise the clot and strut interaction during the case and this provides valuable feedback for clot removal."
Clinical study outcomes from the company's TREVO and TREVO2 studies have yielded robust clinical evidence, demonstrating high revascularisation and a high rate of clinical outcomes compared with the earlier generation Merci retriever.
The clinicians participating in the Trevo retriever registry, a multi-centre, international data collection study, will now be collecting real world data on the Trevo XP ProVue retriever following its 510(k) market clearance by the US Food and Drug Administration (FDA) and clearance in other markets.
Stryker neurovascular division president Mark Paul said: "We set a new standard in stent retriever technology with the launch of the first Trevo ProVue Retriever.
"This second generation device expands the ProVue line and demonstrates our ongoing dedication to providing physicians with the most advanced tools available."
Image: Trevo ProVue Retriever. Photo: courtesy of Stryker Corporation/ PRNewswire.